Last reviewed · How we verify
Vehicle of Ophthalmic Loteprednol Etabonate
Vehicle of Ophthalmic Loteprednol Etabonate is a corticosteroid Small molecule drug developed by Bausch & Lomb Incorporated. It is currently in Phase 3 development for Treatment of inflammation and pain associated with ocular surgery.
Loteprednol etabonate is a corticosteroid that reduces inflammation by inhibiting the production of prostaglandins.
Loteprednol etabonate is a corticosteroid that reduces inflammation by inhibiting the production of prostaglandins. Used for Treatment of inflammation and pain associated with ocular surgery.
At a glance
| Generic name | Vehicle of Ophthalmic Loteprednol Etabonate |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | corticosteroid |
| Target | glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
It does this by binding to the glucocorticoid receptor, which then inhibits the transcription of pro-inflammatory genes. This leads to a decrease in the production of prostaglandins, which are mediators of inflammation.
Approved indications
- Treatment of inflammation and pain associated with ocular surgery
Common side effects
- Increased intraocular pressure
Key clinical trials
- Cyclosporine 0.1% / Loteprednol 0.2% Effect on Anterior Segment Normalization (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease (PHASE2)
- LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease (PHASE2)
- Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease (PHASE3)
- Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vehicle of Ophthalmic Loteprednol Etabonate CI brief — competitive landscape report
- Vehicle of Ophthalmic Loteprednol Etabonate updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI
Frequently asked questions about Vehicle of Ophthalmic Loteprednol Etabonate
What is Vehicle of Ophthalmic Loteprednol Etabonate?
How does Vehicle of Ophthalmic Loteprednol Etabonate work?
What is Vehicle of Ophthalmic Loteprednol Etabonate used for?
Who makes Vehicle of Ophthalmic Loteprednol Etabonate?
What drug class is Vehicle of Ophthalmic Loteprednol Etabonate in?
What development phase is Vehicle of Ophthalmic Loteprednol Etabonate in?
What are the side effects of Vehicle of Ophthalmic Loteprednol Etabonate?
What does Vehicle of Ophthalmic Loteprednol Etabonate target?
Related
- Drug class: All corticosteroid drugs
- Target: All drugs targeting glucocorticoid receptor
- Manufacturer: Bausch & Lomb Incorporated — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Treatment of inflammation and pain associated with ocular surgery
- Compare: Vehicle of Ophthalmic Loteprednol Etabonate vs similar drugs
- Pricing: Vehicle of Ophthalmic Loteprednol Etabonate cost, discount & access